Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.07
MKGAY's Cash to Debt is ranked lower than
59% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. MKGAY: 1.07 )
Ranked among companies with meaningful Cash to Debt only.
MKGAY' s 10-Year Cash to Debt Range
Min: 0.45  Med: 9999.00 Max: No Debt
Current: 1.07
Equity to Asset 0.46
MKGAY's Equity to Asset is ranked lower than
74% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MKGAY: 0.46 )
Ranked among companies with meaningful Equity to Asset only.
MKGAY' s 10-Year Equity to Asset Range
Min: 0.45  Med: 0.48 Max: 0.57
Current: 0.46
0.45
0.57
F-Score: 7
Z-Score: 1.90
M-Score: -2.54
WACC vs ROIC
8.17%
20.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 15.68
MKGAY's Operating margin (%) is ranked higher than
73% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.92 vs. MKGAY: 15.68 )
Ranked among companies with meaningful Operating margin (%) only.
MKGAY' s 10-Year Operating margin (%) Range
Min: 2.84  Med: 10.20 Max: 19.54
Current: 15.68
2.84
19.54
Net-margin (%) 10.35
MKGAY's Net-margin (%) is ranked higher than
64% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. MKGAY: 10.35 )
Ranked among companies with meaningful Net-margin (%) only.
MKGAY' s 10-Year Net-margin (%) Range
Min: 2.91  Med: 8.09 Max: 49.88
Current: 10.35
2.91
49.88
ROE (%) 19.37
MKGAY's ROE (%) is ranked higher than
80% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.43 vs. MKGAY: 19.37 )
Ranked among companies with meaningful ROE (%) only.
MKGAY' s 10-Year ROE (%) Range
Min: 3.86  Med: 10.17 Max: 56.55
Current: 19.37
3.86
56.55
ROA (%) 9.22
MKGAY's ROA (%) is ranked higher than
72% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. MKGAY: 9.22 )
Ranked among companies with meaningful ROA (%) only.
MKGAY' s 10-Year ROA (%) Range
Min: 2.33  Med: 4.94 Max: 30.58
Current: 9.22
2.33
30.58
ROC (Joel Greenblatt) (%) 86.63
MKGAY's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.24 vs. MKGAY: 86.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MKGAY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 8.06  Med: 31.64 Max: 53.26
Current: 86.63
8.06
53.26
Revenue Growth (3Y)(%) 3.80
MKGAY's Revenue Growth (3Y)(%) is ranked lower than
59% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. MKGAY: 3.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MKGAY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 4.45 Max: 15.8
Current: 3.8
0
15.8
EBITDA Growth (3Y)(%) 6.50
MKGAY's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 494 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. MKGAY: 6.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MKGAY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 5.35 Max: 14
Current: 6.5
0
14
EPS Growth (3Y)(%) 24.20
MKGAY's EPS Growth (3Y)(%) is ranked higher than
77% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. MKGAY: 24.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MKGAY' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: 15.70 Max: 51.8
Current: 24.2
0
51.8
» MKGAY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MKGAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 15.37
MKGAY's P/E(ttm) is ranked higher than
81% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.60 vs. MKGAY: 15.37 )
Ranked among companies with meaningful P/E(ttm) only.
MKGAY' s 10-Year P/E(ttm) Range
Min: 10.19  Med: 25.85 Max: 261.35
Current: 15.37
10.19
261.35
Forward P/E 4.80
MKGAY's Forward P/E is ranked higher than
78% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.47 vs. MKGAY: 4.80 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 15.30
MKGAY's PE(NRI) is ranked higher than
81% of the 478 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.00 vs. MKGAY: 15.30 )
Ranked among companies with meaningful PE(NRI) only.
MKGAY' s 10-Year PE(NRI) Range
Min: 10.19  Med: 25.87 Max: 261.35
Current: 15.3
10.19
261.35
P/B 0.79
MKGAY's P/B is ranked higher than
92% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. MKGAY: 0.79 )
Ranked among companies with meaningful P/B only.
MKGAY' s 10-Year P/B Range
Min: 0.35  Med: 0.60 Max: 1.05
Current: 0.79
0.35
1.05
P/S 3.01
MKGAY's P/S is ranked higher than
77% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. MKGAY: 3.01 )
Ranked among companies with meaningful P/S only.
MKGAY' s 10-Year P/S Range
Min: 0.59  Med: 1.76 Max: 7.96
Current: 3.01
0.59
7.96
PFCF 15.76
MKGAY's PFCF is ranked higher than
84% of the 274 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.71 vs. MKGAY: 15.76 )
Ranked among companies with meaningful PFCF only.
MKGAY' s 10-Year PFCF Range
Min: 5.92  Med: 13.27 Max: 24.94
Current: 15.76
5.92
24.94
POCF 11.43
MKGAY's POCF is ranked higher than
83% of the 393 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.63 vs. MKGAY: 11.43 )
Ranked among companies with meaningful POCF only.
MKGAY' s 10-Year POCF Range
Min: 3.04  Med: 10.03 Max: 18.76
Current: 11.43
3.04
18.76
EV-to-EBIT 2.54
MKGAY's EV-to-EBIT is ranked higher than
97% of the 491 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.81 vs. MKGAY: 2.54 )
Ranked among companies with meaningful EV-to-EBIT only.
MKGAY' s 10-Year EV-to-EBIT Range
Min: 2.4  Med: 12.70 Max: 114.2
Current: 2.54
2.4
114.2
Shiller P/E 28.15
MKGAY's Shiller P/E is ranked higher than
60% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.72 vs. MKGAY: 28.15 )
Ranked among companies with meaningful Shiller P/E only.
MKGAY' s 10-Year Shiller P/E Range
Min: 10.43  Med: 27.79 Max: 41.37
Current: 28.15
10.43
41.37
Current Ratio 2.61
MKGAY's Current Ratio is ranked higher than
57% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. MKGAY: 2.61 )
Ranked among companies with meaningful Current Ratio only.
MKGAY' s 10-Year Current Ratio Range
Min: 1.2  Med: 1.66 Max: 3.09
Current: 2.61
1.2
3.09
Quick Ratio 2.27
MKGAY's Quick Ratio is ranked higher than
62% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. MKGAY: 2.27 )
Ranked among companies with meaningful Quick Ratio only.
MKGAY' s 10-Year Quick Ratio Range
Min: 0.89  Med: 1.24 Max: 2.62
Current: 2.27
0.89
2.62
Days Inventory 87.78
MKGAY's Days Inventory is ranked higher than
62% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.99 vs. MKGAY: 87.78 )
Ranked among companies with meaningful Days Inventory only.
MKGAY' s 10-Year Days Inventory Range
Min: 162.19  Med: 207.70 Max: 272.47
Current: 87.78
162.19
272.47
Days Sales Outstanding 38.74
MKGAY's Days Sales Outstanding is ranked higher than
80% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.80 vs. MKGAY: 38.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
MKGAY' s 10-Year Days Sales Outstanding Range
Min: 58.87  Med: 72.39 Max: 102.54
Current: 38.74
58.87
102.54

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.12
MKGAY's Dividend Yield is ranked lower than
56% of the 646 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.41 vs. MKGAY: 1.12 )
Ranked among companies with meaningful Dividend Yield only.
MKGAY' s 10-Year Dividend Yield Range
Min: 0.85  Med: 1.46 Max: 5.19
Current: 1.12
0.85
5.19
Dividend Payout 0.36
MKGAY's Dividend Payout is ranked lower than
55% of the 394 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. MKGAY: 0.36 )
Ranked among companies with meaningful Dividend Payout only.
MKGAY' s 10-Year Dividend Payout Range
Min: 0.88  Med: 1.31 Max: 5.77
Current: 0.36
0.88
5.77
Dividend growth (3y) 15.00
MKGAY's Dividend growth (3y) is ranked higher than
70% of the 255 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. MKGAY: 15.00 )
Ranked among companies with meaningful Dividend growth (3y) only.
MKGAY' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 0.00 Max: 15
Current: 15
0
15
Yield on cost (5-Year) 1.12
MKGAY's Yield on cost (5-Year) is ranked lower than
63% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.64 vs. MKGAY: 1.12 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MKGAY' s 10-Year Yield on cost (5-Year) Range
Min: 0.85  Med: 1.46 Max: 5.19
Current: 1.12
0.85
5.19

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.65
MKGAY's Price/Tangible Book is ranked lower than
62% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. MKGAY: 5.65 )
Ranked among companies with meaningful Price/Tangible Book only.
MKGAY' s 10-Year Price/Tangible Book Range
Min: 1.49  Med: 6.10 Max: 47.73
Current: 5.65
1.49
47.73
Price/Projected FCF 1.41
MKGAY's Price/Projected FCF is ranked higher than
96% of the 319 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.70 vs. MKGAY: 1.41 )
Ranked among companies with meaningful Price/Projected FCF only.
MKGAY' s 10-Year Price/Projected FCF Range
Min: 0.33  Med: 1.21 Max: 1.86
Current: 1.41
0.33
1.86
Price/Median PS Value 0.86
MKGAY's Price/Median PS Value is ranked higher than
86% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. MKGAY: 0.86 )
Ranked among companies with meaningful Price/Median PS Value only.
MKGAY' s 10-Year Price/Median PS Value Range
Min: 0.36  Med: 0.99 Max: 4.43
Current: 0.86
0.36
4.43
Price/Peter Lynch Fair Value 0.56
MKGAY's Price/Peter Lynch Fair Value is ranked higher than
89% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.72 vs. MKGAY: 0.56 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MKGAY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.44  Med: 0.55 Max: 4.07
Current: 0.56
0.44
4.07
Price/Graham Number 1.02
MKGAY's Price/Graham Number is ranked higher than
83% of the 360 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.37 vs. MKGAY: 1.02 )
Ranked among companies with meaningful Price/Graham Number only.
MKGAY' s 10-Year Price/Graham Number Range
Min: 0.65  Med: 1.08 Max: 2.9
Current: 1.02
0.65
2.9
Earnings Yield (Greenblatt) (%) 39.32
MKGAY's Earnings Yield (Greenblatt) (%) is ranked higher than
98% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MKGAY: 39.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MKGAY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.9  Med: 7.80 Max: 41.3
Current: 39.32
0.9
41.3
Forward Rate of Return (Yacktman) (%) 42.41
MKGAY's Forward Rate of Return (Yacktman) (%) is ranked higher than
94% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.88 vs. MKGAY: 42.41 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MKGAY' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 7  Med: 40.80 Max: 52.4
Current: 42.41
7
52.4

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 13,983 16,523 16,939
EPS($) 5.20 6.33 6.45
EPS without NRI($) 5.20 6.33 6.45

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:LSE:0NZZ, TKPYY, TEVA, AGN, FRX » details
Traded in other countries:0O14.UK, MER.Switzerland, MRK.Germany,
Merck KGaA is a pharmaceutical and chemical company founded in 1668 in Darmstadt. It operates as a manufacturer of standard and specialty chemicals for the laboratory and industry. The Company researches drugs in the areas oncology and neurodegenerative as well as autoimmune and inflammatory diseases. The Company operate its businesses in four divisions: Merck Serono (prescription medicines), Consumer Health (over-the-counter pharmaceuticals), Performance Materials (high-tech chemicals) and Merck Millipore (products for pharmaceutical research and biotechnology).:. Within the Merck Serono division, the Company researches on therapeutic areas and prescription drugs of chemical and biotechnological origin. The Consumer Health division comprises the over-the-counter products for preventive health care and self-treatment of minor ailments. The Merck Serono and Consumer Health divisions form together the Company's Pharmaceutical business sector. The Merck Millipore division comprises the activities of the Millipore Corporation. The Performance Materials division consists mainly of the Liquid Crystals and Pigments & Cosmetics business units. The Company also markets cardiovascular, fertility, endocrinology, and over-the-counter products as well as products for flat screens and the pharmaceutical, food, cosmetics, packaging, and coatings.
» More Articles for MKGAY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Merck KGaA Earnings Q2, 2015 Sep 01 2015
Merck in Indien Aug 28 2015
Merck Places Euro Bonds Amounting to € 2.1 Billion Aug 27 2015
Merck Accelerator Program Participants Selected Aug 27 2015
Galactic Sparkle: The New Miraval® Cosmic Pigment Range from Merck Aug 14 2015
Eisai Co., Ltd. Earnings Q2*, 2015 Aug 11 2015
European Stocks Drop as German Consumer Confidence Shaky Aug 11 2015
Merck Secures All Antitrust Approvals for Sigma-Aldrich Acquisition Aug 11 2015
Valeant Pharmaceuticals International, Inc. Earnings Q2*, 2015 Aug 10 2015
Merck Reports Sales and Earnings Growth in Q2 2015 Aug 06 2015
Valeant Pharmaceuticals International, Inc. Earnings Q2*, 2015 Aug 03 2015
Merck and Nano-C Present Enhanced Materials for Organic Photovoltaics Aug 03 2015
Merck Millipore Adds Protein Pegylation to Portfolio of Services for Biopharmaceutical Industry... Aug 03 2015
Merck Announces Application Period for Start-ups Jul 30 2015
Valeant Pharmaceuticals International, Inc. Earnings Analysis: By the Numbers Jul 30 2015
Merck Appoints Isabel De Paoli as new Head of Group Communications Jul 30 2015
Juniper Pharmaceuticals Announces Regulatory Approvals for CRINONE® Progesterone Gel in Nine New EU... Jul 28 2015
Merck Serono Awards € 20,000 to Innovation Cup Winners Jul 21 2015
Merck Receives EU-Approval to Extend Kuvan Use to Children with PKU Below 4 Years of Age Jul 20 2015
13th "Premio Letterario Merck" Honors Authors for Creating Bridges Between Science and Literature Jul 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK